Reuters news agency reported on Friday that the US Food and Drug Administration (FDA), on 25 February 2021, approved storage and transportation of the COVID-19 vaccine developed by Pfizer Inc and German partner BioNTech SE at standard freezer temperatures for up to two weeks instead of ultra-cold conditions.
Reportedly, the companies had asked the US health regulator last week to relax requirements for their COVID-19 vaccine to be stored at ultra-low temperatures, potentially allowing it to be kept in pharmacy freezers.
The director of the FDA's Centre for Biologics Evaluation and Research, Peter Marks, was quoted as saying: "Alternative temperature for transportation and storage will help ease the burden of procuring ultra-low cold storage equipment for vaccination sites and should help to get vaccine to more sites."
In December 2020, the US FDA had granted emergency use authorisation to the Pfizer-BioNTech vaccine and current label to be stored at temperatures between minus 80ºC and minus 60ºC, implying it has to be shipped in specially designed containers.
European Commission approves Camurus' once-monthly octreotide treatment for acromegaly
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
AbbVie agrees to acquire Capstan Therapeutics
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes